Call For Evidence Consultation Launched For ABI Strategy

A Call for Evidence has been launched for the recently agreed cross departmental Government strategy for Acquired Brain Injury (ABI). The UK Acquired Brain Injury Forum (UKABIF) joined other brain injury charities and organisations and people with acquired brain injury at the House of Commons this week where the Minister of State for Care and…

WFNR Franz Gerstenbrand Award 2022

Brain Awareness Week – WFNR Franz Gerstenbrand Award 2022 now open for entries As we mark Brain Awareness Week, I’m delighted to announce that the World Federation for Neurorehabilitation (WFNR) Franz Gerstenbrand Award 2022 is now open, and we particularly encourage entries from individuals under the age of 35 years who are clinicians, researchers or…

Music Therapy strikes a chord with traumatised emergency workers ​

The Blue Light Symphony Orchestra (BLSO), in collaboration with Chroma, successfully completed a pilot project delivering group Music Therapy to emergency service workers to help them recover from traumatic experiences. Working with Surrey and Sussex Police, Surrey and East Sussex Fire and Rescue and Southeast Coast Ambulance Service, the project, a UK first, delivered a…

Copaxone® for use in breastfeeding mothers with RMS

Change to COPAXONE® (Glatiramer Acetate (GA)) Summary of Product Characteristics (SmPC) in breastfeeding is relevant for the Multiple Sclerosis (“MS”) community and provides information for neurologists and patients of the positive benefit/risk balance of use in breastfeeding Relapsing Multiple Sclerosis (RMS) is 2-3 times more likely to affect womeni, with diagnosis most common during childbearing years The SmPC update…

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Positive topline results show the Phase 3 RAISE (NCT04115293) zilucoplan trial met primary and all key secondary endpoints in adults with generalised myasthenia gravis The results show a favourable safety profile and good tolerability   UCB plans to proceed with zilucoplan regulatory submissions later this year  Results follow recent positive topline data from the Phase…

UKABIF Award Winners Announced at Time for Change Summit

The winners of the annual UK Acquired Brain Injury Forum (UKABIF) awards have been honoured at this year’s Time for Change summit. The Awards include the UKABIF Film Award, the Mike Barnes Award for Innovation, the Stephen McAleese Award for Inspiration and the UKABIF Poster Award. The Awards were kindly sponsored by Elysium Healthcare. Nicola…

ACNR Podcast – celebrating 20 years of ACNR

It is a great pleasure to mark ACNR’s 20th anniversary with a new departure for the reviews section. This is our first podcast review. And what better inaugural podcast to review than the ACNR’s very own, in the form of an interview by Sri Kodali. Sri questions no less a pair than Rachael Hansford, ACNR…

Positive phase III data for Neurocrine’s Ingrezza in Huntington’s disease

Neurocrine Biosciences has recently announced that its pipeline asset, Ingrezza (valbenazine), achieved the primary endpoint of reducing the symptoms of chorea (involuntary muscle movements) associated with Huntington’s disease (HD) in the Phase III clinical trial, KINECT-HD (NCT04102579). This will propel Ingrezza into a dominant position in the HD market, due to its convenient once-daily dosing…

UCB announces positive Phase 3 results for rozanolixizumab in generalised myasthenia gravis

Positive topline results from UCB MycarinG study investigating the efficacy and safety of rozanolixizumab in patients with generalised myasthenia gravis (gMG) Study met primary and all secondary endpoints with statistical significance Rozanolixizumab was well tolerated with no new observed safety signals  UCB plans regulatory submissions for rozanolixizumab in gMG from Q3 2022  December 10th, 2021…